A resolution designating July 16, 2025, as "Glioblastoma Awareness Day".

Legislative Summary: S.Res. 285

Overview

S.Res. 285 is a Senate resolution that officially designates July 16, 2025, as "Glioblastoma Awareness Day." The resolution serves as a formal acknowledgment by the U.S. Senate of the severity of glioblastoma—the most aggressive form of primary malignant brain tumor—and the urgent need for increased public awareness, research, and funding to improve patient outcomes.

Purpose and Intent

The primary intent of this resolution is to shine a spotlight on the devastating impact of glioblastoma on patients and their families. By designating a specific awareness day, the Senate aims to:
* Increase Visibility: Bring public attention to the medical challenges and high mortality rates associated with this specific type of brain cancer.
* Advocate for Research: Encourage a collaborative research effort between government, private, and nonprofit sectors to develop better treatments and early detection methods.
* Support Patients: Honor those suffering from the disease and recognize the vital role of caregivers.

Key Provisions and Acknowledgments

While a Senate Resolution is a non-binding expression of the Senate's will (rather than a law that mandates new regulations or spending), S.Res. 285 makes several critical points:

• Designation: Formally establishes July 16, 2025, as Glioblastoma Awareness Day.
• Medical Recognition: Recognizes the criticality of molecular biomarker testing in the diagnosis and treatment of the disease.
• Support for Infrastructure: Expresses support for the Glioblastoma Therapeutics Network (GTN), established by the National Cancer Institute in 2020, as a primary vehicle for moving preclinical studies into clinical trials.
• Call to Action: Urges continued investment in research to address the fact that very few FDA-approved drugs or devices have been developed for glioblastoma since the 1920s.

Impact and Affected Parties

The resolution highlights the plight of several key groups:
* Patients: Over 13,000 individuals estimated to be diagnosed in 2025, facing a low 5-year survival rate (6.9%) and high out-of-pocket medical costs.
* Caregivers and Families: Acknowledges the emotional and financial burden on those supporting patients.
* Medical Researchers: Encourages a more collaborative, multi-institutional approach to accelerate the discovery of effective therapies.

Procedural Timeline

• Introduced/Passed: The resolution was introduced and agreed to by Unanimous Consent in the Senate on June 17, 2025.
• Bipartisan Support: The resolution saw broad support from a diverse group of co-sponsors from both parties.